Results from first melanoma trial using LOAd703 tumor microenvironment gene engineering in combination with immune checkpoint inhibition is published in Nature Communications
Final results from the LOKON003 phase 1/2 trial: LOAd703 may re-sensitize therapy resistant melanoma patients to continued checkpoint antibody treatment.